



## Genexine, Inc.

CEO  
Young Chul Sung, PhD

Location  
700 Daewangpangyo-ro, Korea  
Bio ParkBldg. B, Bundang-gu,  
Seongnam-si, Gyeonggi-do  
13488, Republic of Korea

Specialty  
Cancer Immunotherapeutics,  
DNA Therapeutic Vaccines,  
Next Generation Long-acting  
Biologics

Tel / Fax / E-mail  
T. 82-31-628-3200  
F. 82-31-628-3229  
E. bd@genexine.com  
ir@genexine.com

Genexine (KOSDAQ, 095700) is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics. Our goal is to bring to patients medicines that will transform their lives. hyFc platform and DNA therapeutic vaccine platform are our own core proprietary technologies, which are designed to drive the discovery of a wide range of differentiated therapeutics.

### R&D Pipeline

#### GX-I7 (Long-acting IL-7)

Areas	Indication	Regimen	Non-clinical	Phase 1	Phase 2	Site
	Healthy Volunteers	SAD				KR
Immuno-Oncology	Solid Tumor	Mono				KR
		Mono				CN
		Mono				KR/US
	Glioblastoma	TMZ Combo				US
		Triple Negative Breast Cancer	Pembrolizumab Combo			
	Skin Cancer	Atezolizumab Combo				US

#### GX-188 (HPV DNA Therapeutic Vaccine)

Indication	Regimen	Non-clinical	Phase 1	Phase 2	Site
Cervical Cancer	Pembrolizumab Combo				KR

#### GX-H9 (Long-acting hGH)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Adult Growth hormone Deficiency					KR/EU
Pediatric Growth hormone Deficiency					KR/EU

#### GX-G3 (Long-acting G-CSF)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Neutropenia					KR/EU

#### GX-E4 (Long-acting EPO)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
CKD-induced Anemia					Mutational Phase 3 on-going ASEAN/AU

#### GX-G6 (Long-acting GLP-1)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Type 2 Diabetes					Phase 2 IND Approved EU

#### GX-G8 (Long-acting GLP-2)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Short Bowel Syndrome					Phase 1 IND Approved EU

#### GX-P1 (Long-acting PD-L1)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Autoimmune diseases organ transplantation					Phase 1 IND Approved KR